Literature DB >> 12371303

Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?

Brent Kvern1.   

Abstract

Entities:  

Year:  2002        PMID： 12371303      PMCID： PMC2214104     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  5 in total

Review 1.  The coxibs, selective inhibitors of cyclooxygenase-2.

Authors:  G A FitzGerald; C Patrono
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

2.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

Review 3.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

4.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

5.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.

Authors:  P S Sanmuganathan; P Ghahramani; P R Jackson; E J Wallis; L E Ramsay
Journal:  Heart       Date:  2001-03       Impact factor: 5.994
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.